Cargando…

Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause

OBJECTIVE: To understand prevalence, severity, impact, and treatment of vasomotor symptoms associated with menopause, using cross-sectional survey data. METHODS: This online, two-part survey was conducted in East Asia among women 40-65 years recruited from established online panels (Edelman, Beijing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qi, Chae, Hee-Dong, Hsiao, Sheng-Mou, Xie, Jipan, Blogg, Martin, Sumarsono, Budiwan, Kim, Soyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060817/ https://www.ncbi.nlm.nih.gov/pubmed/35231007 http://dx.doi.org/10.1097/GME.0000000000001949

Ejemplares similares

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
por: Johnson, Kimball A, et al.
Publicado: (2023)

Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
por: Yang, Yihui, et al.
Publicado: (2023)

Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey
por: DePree, Barbara, et al.
Publicado: (2023)

Vasomotor and physical menopausal symptoms are associated with sleep quality
por: Kim, Min-Ju, et al.
Publicado: (2018)

Association of Menopausal Vasomotor Symptoms With Increased Bone Turnover During the Menopausal Transition
por: Crandall, Carolyn J, et al.
Publicado: (2011)

Treatment Strategies for Reducing the Burden of Menopause-Associated Vasomotor Symptoms
por: Umland, Elena M.
Publicado: (2008)

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms
por: Ryu, Ki-Jin, et al.
Publicado: (2020)

Hops for Menopausal Vasomotor Symptoms: Mechanisms of Action
por: Abdi, Fatemeh, et al.
Publicado: (2016)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms
por: Singhal, Savita Rani, et al.
Publicado: (2016)

Psychosomatic and vasomotor symptom changes during transition to menopause
por: Augoulea, Areti, et al.
Publicado: (2019)

MON-387 Pheochromocytoma Masquerading as Vasomotor Menopausal Symptoms
por: Xhikola, Majlinda, et al.
Publicado: (2019)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
por: Pachman, Deirdre R, et al.
Publicado: (2010)

Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol)
por: Goldstein, Karen M., et al.
Publicado: (2016)

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms
por: Langley, Paul C
Publicado: (2023)

The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms
por: Egras, Amy M, et al.
Publicado: (2010)

Erratum to: Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol)
por: Goldstein, Karen M., et al.
Publicado: (2016)

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review
por: Utian, Wulf H
Publicado: (2005)

Investigation of the relationship between personality characteristics and vasomotor symptoms in menopausal women
por: Ghorbani, Mahboubeh, et al.
Publicado: (2016)

RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause
por: Kalkan, R, et al.
Publicado: (2020)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Short-Term Isoflavone Intervention in the Treatment of Severe Vasomotor Symptoms after Surgical Menopause: A Case Report and Literature Review
por: Teekachunhatean, Supanimit, et al.
Publicado: (2015)

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
por: Pinkerton, JoAnn V., et al.
Publicado: (2015)

Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis
por: Muka, Taulant, et al.
Publicado: (2016)

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden
por: Nappi, Rossella E., et al.
Publicado: (2021)

Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
por: Pirotta, Marie, et al.
Publicado: (2014)

Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms
por: Lambert, Max Norman Tandrup, et al.
Publicado: (2017)

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review
por: Iliodromiti, S, et al.
Publicado: (2019)

A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial
por: Barnard, Neal D., et al.
Publicado: (2023)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
por: Lee, Kyu-Sung, et al.
Publicado: (2017)

Erratum to: Acupuncture for menopausal vasomotor symptoms: study protocol for a randomised controlled trial
por: Pirotta, Marie, et al.
Publicado: (2015)

Vasomotor Symptoms During Menopause: A Practical Guide on Current Treatments and Future Perspectives
por: Khan, Saira J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6314b9ehmcm5beqsg6gq9k1070